Laurus Synthesis is the company's CDMO subsidiary, with the US, European Union and Japan as the three most important markets. Laurus Labs has announced three major capacity expansions including a microbial fermentation facility in Vizag expected to go online by the end of 2026.
Cyborg Score Rationale
9-month revenues reached ₹5,001 Cr with EBITDA of ₹1,303 Cr as of Q3 FY26. EBITDA margins expanded to close to 25% due to better operating leverage and product mix. The company demonstrates strong growth, regulatory approvals, and strategic expansion plans, though operating in a competitive generic pharma landscape.
Top Insights
Three major capacity expansions underway: microbial fermentation, gene therapy facility, and finished formulation capability
Manufacturing units have received approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA
EBITDA margins expanded by 10.5 percentage points to close to 25% in Q1 FY26
Trailing twelve month revenue of $734M with growing CDMO and formulation segments
Named Competitors
Sun Pharma — Large integrated pharma with APIs and formulations
Cipla — Diversified pharma with generic APIs and formulations
Glenmark — API manufacturer and generic formulations provider
Lupin — Pharma company with API and formulation portfolio